Notable 52-Week Highs and Lows of the Day 12/17: (BAC) (CX) (LUV) High; (END) (LNET) (TZYM) Low


FREE Breaking News Alerts from StreetInsider.com!

E-mail Address
December 17, 2012 2:04 PM EST Send to a Friend
This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today.

52-Week High:
  • Bank of America Corp. (NYSE: BAC) $10.90. BofA and other financials ticking higher as lawmakers are nearing a consensus over the fiscal cliff. There is now just two weeks until about $600 billion of tax hikes and spending cuts kick in, which will largely have an adverse impact on the middle class.

    BofA moved as much as 3 percent higher Monday.

  • Cemex SAB (NYSE: CX) high of $9.59. Cemex making a strong move above the $9.50 level. Shares have been trending higher, but saw resistance at the $9.15 - $9.20 level.

  • Southwest Airlines Co. (NYSE: LUV) high of $10.43. Continuing higher after a positive outlook for the industry issued by the International Air Transport Association (IATA) last Thursday. Dahlman Rose also commented on recent performance in the segment, upgrading US Airways (NYSE: LCC) in the process.

  • Tesoro Corp (NYSE: TSO) high of $45.41. Tesoro continuing higher following affiliate Tesoro Logistics LP (NYSE: TLLP) moving to acquire Chevron assets last week. For more on the deal, click here.
52-Week Low:
  • Endeavour International Corp. (NYSE: END low of $4.89. Endeavour said purchase agreements to acquire ConocoPhillips’(NYSE: COP) interest in three producing U.K. oil fields in the Central North Sea were terminated. Global Hunter also downgraded the stock today. For more, click here.

  • LodgeNet Interactive (Nasdaq: LNET) low of $0.08. LodgeNet entered into an amended Forbearance Agreement agreement with lenders.

  • Tranzyme Pharma (Nasdaq: TZYM) low of $0.56. Tranzyme announced it is discontinuing and immediately ending patient enrollment in DIGEST, a Phase 2b trial in diabetic patients receiving TZP-102 for the management of symptoms of gastroparesis, due to insufficient efficacy. The decision followed a planned interim futility analysis, which examined patients' responsiveness to thrice daily oral dosing of 10mg of TZP-102 or placebo at the end of weeks 4 and 8 of a 12 week trial.

    Shares slipped 35 percent today.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here


You May Also Be Interested In


Related Categories

Special Reports

Related Entities

Bank of America

Add Your Comment